Clinical trial

Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation…

NCT00113828 · Massachusetts General Hospital, Other · Terminated

Key facts

NCT number NCT00113828
Title Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Official title Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Lead sponsor Massachusetts General Hospital, Other
Collaborators Dana-Farber Cancer Institute
Status Terminated
Phase Phase 2
Study type Interventional
Conditions Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Intervention type Procedure
Interventions Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant, T-cell depleted peripheral blood stem cell transplant
Enrollment 5
Start date Dec 1, 2004
Primary completion Mar 1, 2007
Completion Mar 1, 2007
First posted Jun 13, 2005
Last update posted Mar 15, 2018
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies